Table 4

Joint-level risk of progression to CS according to ultrasound findings at baseline

Time to CS
Joint scoreProgressed to CS: % (n/N)Median (1st, 3rd quartile)MeanHR (95% CI), p valueC
All joints included
GS=03.2% (106/3353)* (*, *)75.5Reference0.62
GS=16.0% (37/621)* (*, *)69.51.9 (1.2 to 3.2), p=0.010
GS≥210.1% (38/378)* (*, *)67.72.8 (0.4 to 20.3), p=0.311
PD=03.5% (146/4222)* (*, *)75.2Reference0.60
PD=115.2% (14/92)* (44.4, *)52.75.2 (2.8 to 9.6), p<0.001
PD=255.3% (21/38)7.1 (3.0, *)20.331.3 (15.6 to 62.9), p<0.001
ERO=04.1% (178/4314)* (*, *)74.6Reference0.51
ERO=17.9% (3/38)* (36.6, *)51.02.8 (0.9 to 8.9), p=0.079
MTPs excluded
GS=03.1% (79/2528)* (*, *)76.0Reference0.66
GS=19.2% (33/359)* (50.1, *)59.63.3 (2.0 to 5.3), p<0.001
GS≥225.7% (27/105)* (12.0, *)51.79.4 (5.1 to 17.5), p<0.001
PD=03.8% (111/2899)* (*, *)74.9Reference0.61
PD=118.2% (12/66)* (44.4, *)51.75.0 (2.6 to 9.9), p<0.001
PD=259.3% (16/27)3.7 (1.2, *)18.132.0 (15.1 to 67.5), p<0.001
ERO=04.6% (138/2984)* (*, *)74.2Reference0.50
ERO=112.5% (1/8)36.6 (36.6, *)36.63.1 (0.6 to 17.3), p=0.195
  • *Value could not be calculated due to limitations in the pattern of progression and censoring.

  • C, Harrell's C; CS, clinical synovitis; ERO, erosion; GS, grey scale; MTPs, metatarsophalangeal joints; PD, power Doppler.